Outcomes

The evidence for dulaglutide outcomes is limited in the provided literature, with most studies focusing on broader GLP-1 receptor agonist classes rather than dulaglutide specifically.

Metabolic and Glycemic Outcomes

One pilot study directly compared dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes. However, specific outcome data from this study are not detailed in the available evidence.

A comparative effectiveness study examined GLP-1 receptor agonists (including dulaglutide) versus oral agents for insulin discontinuation in type 2 diabetes using target trial emulation methodology. The specific results for dulaglutide within this analysis are not provided in the current evidence.

Safety Outcomes

Diabetic Retinopathy Risk

A systematic review and meta-analysis assessed the risk of diabetic retinopathy progression with GLP-1 receptor agonists as a class. While this included dulaglutide, the specific risk profile for dulaglutide alone is not separately reported in the available evidence.

Clinical Trial Evidence

Several completed clinical trials provide outcome data:

A Phase 3 study in Japanese participants with type 2 diabetes (NCT01584232) has been completed, though specific outcomes are not detailed in the current evidence
A Phase 4 comparison study between beinaglutide and dulaglutide examining glucose control and weight loss effects in type 2 diabetes patients with overweight or obesity (NCT05005741) has unknown status
A Phase 4 switching study (SURPASS-SWITCH) examining participants transitioning from dulaglutide to tirzepatide has been completed

Evidence Limitations

The current evidence base is insufficient to provide comprehensive outcome data specifically for dulaglutide. Most studies examine GLP-1 receptor agonists as a therapeutic class without isolating dulaglutide-specific results. The individual study results, effect sizes, and safety profiles for dulaglutide require access to full study reports or additional literature not included in this evidence set.

This summary is based on limited available evidence. Consult healthcare providers for complete prescribing information and individualized treatment decisions.

Dulaglutide

Member access required